According to Omthera, the top-line results from EVOLVE show a “highly statistically significant” reduction of triglycerides in all Epanova dose groups.
Omthera Pharmaceuticals Inc. (Princeton, NJ), which has been in trials with its Epanova omega-3 drug for treating patients with very high triglycerides, reported positive results from its most recent Phase III clinical trial. Epanova is a patented formula of free fatty acid forms of EPA and DHA omega-3, which the company says has been shown to exhibit “improved and more predictable bioavailability as compared to the ethyl ester form found in prescription omega-3 products currently available.”
The latest study, the EVOLVE trial, randomized 399 subjects with triglyceride levels of 500 to 2000 mg/dl to take 2, 3, or 4 g of Epanova, or 4 g of olive oil, for 12 weeks. The trial’s primary endpoint was the percentage change in triglyceride level from baseline, with a secondary endpoint of a reduction in non-HDL cholesterol. (Previous Phase III studies on Epanova include two large, placebo-controlled, randomized, double blind studies involving 748 Crohn’s disease patients with normal triglyceride levels.)
According to Omthera, the top-line results from EVOLVE show a “highly statistically significant” reduction of triglycerides in all Epanova dose groups. Specifically, the 2-g group saw median decreases in triglycerides of approximately 26%, while the 4-g dose group saw reductions of 31%.
“We are pleased by the comprehensive lipid benefits shown by Epanova in the EVOLVE study-especially at the 2-g dose, which demonstrated triglyceride lowering comparable to that of 4-g doses of other prescription omega-3 products,” stated Jerry Wisler, Omthera’s CEO, in a press release. “This comparable efficacy of Epanova at a significantly lower dose supports the prior demonstration of improved bioavailability of this free fatty acid formulation versus the ethyl ester form found in other prescription omega-3 products.”
The company’s chief medical officer, Michael Davidson, MD, also stated that positive results from the secondary endpoint-a “meaningful” decrease of 8% in non-HDL cholesterol in both the 2- and 4-g dose groups-is significant as the medical community is increasingly focusing on non-HDL cholesterol as a “more accurate” predictor of CVD risk, especially in patients with hypertriglyceridemia.
He says the company has also completed enrollment and randomization for a new study, the ESPRIT study on 647 patients, which will look at the effects of Epanova in combination with statins for lowering non-HDL cholesterol.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
GC Rieber VivoMega uses AI platform from Intelecy to boost efficiency, quality, and sustainability
August 26th 2024According to the company’s announcement, the AI platform is able to identify real-time deviations or anomalies in GC Rieber VivoMega’s processing facilities and report them via a cloud-based, comprehensive, centralized system.